Dr. Maya Khalil dives into the intricacies of RET+ NSCLC treatments in our 2022 Targeted Therapies Forum. Gain insights as she meticulously compares the efficacy and application of Selpercatinib and Pralsetinib, two leading medications in the field.
Supported by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.
For a deeper understanding and to be a part of the larger conversation on RET+ NSCLC, make sure to visit http://cancerGRACE.org/. Engage with experts and peers in our forum: https://cancergrace.org/forum.”